诱导治疗的作用。
The role of induction therapy.
作者信息
Moremen Jacob R, Skopelja Elaine N, Ceppa DuyKhanh P
机构信息
1 Division of Cardiothoracic Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA ; 2 Ruth Lilly Medical Library, Indiana University School of Medicine, Indianapolis, Indiana, USA.
出版信息
J Thorac Dis. 2014 May;6 Suppl 3(Suppl 3):S309-13. doi: 10.3978/j.issn.2072-1439.2014.03.10.
Abstract
The incidence of esophageal cancer has been steadily increasing. The 5-year survival of esophageal cancer has minimally improved over the past 30 years. In this article, we review the management of esophageal cancer, focusing on the literature investigating the role of induction chemotherapy and radiation therapy.
摘要
食管癌的发病率一直在稳步上升。在过去30年里，食管癌的5年生存率仅有微乎其微的提高。在本文中，我们回顾了食管癌的治疗方法，重点关注研究诱导化疗和放射治疗作用的文献。
相似文献
1
The role of induction therapy.诱导治疗的作用。
J Thorac Dis. 2014 May;6 Suppl 3(Suppl 3):S309-13. doi: 10.3978/j.issn.2072-1439.2014.03.10.
2
Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.食管癌的三联疗法和根治性放化疗：单中心经验及文献综述
Dis Esophagus. 2015 Oct;28(7):612-8. doi: 10.1111/dote.12242. Epub 2014 May 27.
3
The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.三联疗法后仍有残留病灶的食管癌患者化疗的益处
Am J Clin Oncol. 2016 Apr;39(2):136-41. doi: 10.1097/COC.0000000000000036.
4
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes.食管癌的根治性或术前放化疗：治疗模式与生存结果
Ann Thorac Surg. 2016 Jun;101(6):2148-54. doi: 10.1016/j.athoracsur.2015.12.056. Epub 2016 Mar 24.
5
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.顺铂、氟尿嘧啶、放疗及手术三联疗法与单纯手术治疗食管癌的III期试验：癌症和白血病B组9781研究
J Clin Oncol. 2008 Mar 1;26(7):1086-92. doi: 10.1200/JCO.2007.12.9593.
6
Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.新辅助放化疗可改善老年食管癌患者的总生存。
J Geriatr Oncol. 2018 Jan;9(1):40-46. doi: 10.1016/j.jgo.2017.08.010. Epub 2017 Sep 6.
7
Outcomes after surgery for esophageal cancer.食管癌手术后的结果。
Gastrointest Cancer Res. 2007 Sep;1(5):188-96.
8
The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population: patient survival and outcome analysis.三联疗法用于治疗退伍军人中可手术食管癌的疗效：患者生存率及预后分析
Cancer. 2001 Sep 1;92(5):1272-80. doi: 10.1002/1097-0142(20010901)92:5<1272::aid-cncr1448>3.0.co;2-a.
9
The clinical efficacy of consolidation chemotherapy for resectable esophageal squamous cell cancer after trimodality therapy.三联疗法后可切除食管鳞状细胞癌巩固化疗的临床疗效
J Cancer Res Ther. 2016 Jan-Mar;12(1):90-5. doi: 10.4103/0973-1482.148687.
10
Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.局部晚期非小细胞肺癌的放疗与化疗：临床前及早期临床数据
Hematol Oncol Clin North Am. 2004 Feb;18(1):41-53. doi: 10.1016/s0889-8588(03)00138-2.
引用本文的文献
1
Substernal reconstruction following esophagectomy: operation of last resort?食管癌切除术后胸骨后重建：是最后的治疗手段吗？
J Thorac Dis. 2017 Dec;9(12):5040-5045. doi: 10.21037/jtd.2017.11.51.
2
Strategy for chemotherapeutic delivery using a nanosized porous metal-organic framework with a central composite design.使用具有中心复合设计的纳米级多孔金属有机框架进行化疗给药的策略。
Int J Nanomedicine. 2017 Feb 22;12:1465-1474. doi: 10.2147/IJN.S119115. eCollection 2017.
本文引用的文献
1
Preoperative chemoradiotherapy for esophageal or junctional cancer.术前放化疗治疗食管或食管胃交界癌。
N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.
2
Cancer statistics, 2012.癌症统计数据，2012 年。
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
3
Radiotherapy versus surgery within multimodality protocols for esophageal cancer--a meta-analysis of the randomized trials.放疗法与手术联合多模式方案治疗食管癌的疗效比较——随机试验的荟萃分析。
Cancer Treat Rev. 2012 Oct;38(6):599-604. doi: 10.1016/j.ctrv.2011.10.005. Epub 2011 Nov 23.
4
A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).一项比较术后顺铂联合氟尿嘧啶辅助化疗与术前化疗治疗局部晚期食管鳞状细胞癌（JCOG9907）的随机临床试验。
Ann Surg Oncol. 2012 Jan;19(1):68-74. doi: 10.1245/s10434-011-2049-9. Epub 2011 Aug 31.
5
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.可切除食管癌新辅助化疗或放化疗后的生存：更新的荟萃分析。
Lancet Oncol. 2011 Jul;12(7):681-92. doi: 10.1016/S1470-2045(11)70142-5. Epub 2011 Jun 16.
6
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.可切除胃食管腺癌的围手术期化疗与单纯手术比较：FNCLCC 和 FFCD 多中心 III 期试验。
J Clin Oncol. 2011 May 1;29(13):1715-21. doi: 10.1200/JCO.2010.33.0597. Epub 2011 Mar 28.
7
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.术前化疗治疗食管腺癌患者是否需要同期放化疗？一项随机 II 期试验。
Eur J Cancer. 2011 Feb;47(3):354-60. doi: 10.1016/j.ejca.2010.09.009.
8
Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer.食管癌新辅助治疗后组织学肿瘤类型与完全缓解率。
Future Oncol. 2010 Jan;6(1):25-35. doi: 10.2217/fon.09.133.
9
Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction.局部晚期食管胃交界腺癌患者术前化疗与放化疗的III期比较
J Clin Oncol. 2009 Feb 20;27(6):851-6. doi: 10.1200/JCO.2008.17.0506. Epub 2009 Jan 12.
10
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.顺铂、氟尿嘧啶、放疗及手术三联疗法与单纯手术治疗食管癌的III期试验：癌症和白血病B组9781研究
J Clin Oncol. 2008 Mar 1;26(7):1086-92. doi: 10.1200/JCO.2007.12.9593.
Zotero 插件